Skip to main content

Table 2 Baseline echocardiographic findings

From: Left atrial longitudinal strain as a predictor of Cancer therapeutics-related cardiac dysfunction in patients with breast Cancer

  CTRCD (n = 13) No CTRCD (n = 59) p value
LVEDVI (mL/m2) 56.8 ± 10.6 56.5 ± 9.9 0.920
LVESVI (mL/m2) 19.9 ± 5.3 20.3 ± 4.6 0.774
LVEF (%) 65.0 ± 6.4 63.9 ± 5.9 0.564
LVGLS (%) −21.0 ± 2.4 −22.2 ± 2.2 0.086
E (cm/sec) 71.3 ± 10.4 62.7 ± 7.7 0.001
e’ (cm/sec) 8.8 ± 1.4 8.3 ± 1.8 0.379
s’ (cm/sec) 7.9 ± 0.9 7.4 ± 1.0 0.138
E/e’ 8.2 ± 1.0 7.7 ± 1.2 0.201
LAVI (mL/m2) 25.8 ± 3.8 26.0 ± 3.9 0.833
PALS (%) 33.1 ± 5.9 33.8 ± 5.6 0.689
LA conduit strain (%) 19.2 ± 3.4 19.8 ± 3.3 0.550
LA booster strain (%) 13.9 ± 2.5 14.0 ± 2.3 0.905
RVSP (mmHg) 29.3 ± 7.1 32.0 ± 7.3 0.239
  1. CTRCD cancer therapeutics-related cardiac dysfunction, LVEDVI left ventricular end-diastolic volume index, LVESVI left ventricular end-systolic volume index, LVEF left ventricular ejection fraction, LVGLS left ventricular global longitudinal strain, E early diastolic mitral inflow velocity, e’: early diastolic velocity of mitral septal annulus, s’: systolic velocity of mitral septal annulus, LAVI left atrial volume index, PALS peak atrial longitudinal strain, LA left atrium, RVSP right ventricular systolic pressure